Revolutionizing cardiovascular analysis

Early CVD detection made accessible – advanced cardiovascular modeling for clinical precision

CVD – A global health crisis

Cardiovascular disease (CVD) claims 18 million lives each year, making it the world’s leading cause of death. Over 500 million people live with CVD globally, yet current diagnostic tools fail to detect disease early enough, leaving many undiagnosed until life-threatening symptoms appear.

80% of cases
could be prevented

Up to 80% of CVDs are preventable with early detection and intervention. Yet current diagnostic tools lack either the precision or accessibility needed for effective screening, leaving millions undiagnosed until severe symptoms appear.

PAD: the silent pandemic

For a lesser-known CVD, Peripheral Artery Disease (PAD), over 230 million people worldwide are affected – many without symptoms. Because current methods detect only symptomatic cases, early disease is often missed, leading to preventable harm.

$1 trillion crisis
by 2030

CVDs will cost society over 1 trillion USD annually by 2030. Late diagnosis drives these costs, a single stroke costs $122,000 per admission and PAD treatment costs $7,000 per patient yearly. Early detection and prevention is both lifesaving and cost-effective.

CVDs – A global health crisis

Of deaths per year globally

Million affected

%

Without symptoms

The fact is that it doesn’t have to be this way, up to 80% CVDs are preventable with early detection and intervention. The problem is that there are no readily available methods for early and precise detection of CVD signs. BEATLAB changes this.

Advanced cardiovascular modeling for clinical precision

BEATLAB transforms accessible pulse wave measurements into comprehensive cardiovascular analysis. Using proprietary signal processing and physics-based cardiovascular modeling, we identify and locate arterial stenosis and other cardiovascular anomalies before symptoms appear, with high accessibility and at a fraction of the cost of medical imaging technologies.

1.

Identifies cardiovascular anomalies long before symptoms appear and when intervention is most effective.

2.

Delivers detailed cardiovascular insights comparable to medical imaging, but accessible for primary care screening.

3.

Works with standard diagnostic devices, no expensive new hardware required. Analysis results provided in a couple of minutes.

How BEATLAB works step by step

1.

Measure: Non-invasive pulse wave measurements using standard PPG sensors at multiple body locations. Fast (<5 minutes), and accessible in any clinical setting.

2.

Model: Combining proprietary signal processing and physics-based cardiovascular modeling to create a digital twin of the patient’s cardiovascular system, revealing detailed hemodynamic parameters.

3.

Detect and locate: AI-powered analysis identifies and pinpoints cardiovascular anomalies and early CVD signs, providing actionable clinical insights for targeted intervention.

What makes BEATLAB unique

Beyond surrogate markers

Not just blood pressure or pulse wave velocity – comprehensive cardiovascular system analysis.

Clinical-grade from accessible sensors

Medical imaging-level insights without expensive equipment.

Localization, not just detection

Pinpoints anomaly location for precise intervention.

About us

Three co-founders, one mission: making early cardiovascular disease detection accessible to everyone. Driven by personal experiences with CVD, we bring together expertise in cardiovascular modeling, biosignals, AI, and medical device commercialization to transform how CVD is detected and prevented.

Daniel Adin, COO & Co-founder

Leads data science and AI development, architecting the machine learning and digital twin modeling that power BEATLAB’s cardiovascular analysis. Co-founder Escenda Engineering.

Mikael Karlsson, CTO & Co-founder

Inventor of BEATLAB technology and lead researcher. PhD in Flow Acoustics (KTH), co-founder Escenda Engineering. Pioneering the cardiovascular modeling methodology enabling early CVD detection from pulse wave analysis.

Pontus Axblom, CEO & Co-founder

Leads strategy, operations, and business development. Former CEO Bohus Biotech, medical device regulatory consultant, software developer and ex-Accenture. Deep expertise in medical device commercialization and regulatory pathways.